Humanetics receives patent for radiation countermeasure drug
Humanetics obtained a global exclusive license from the Henry M. Jackson Foundation for the Advancement of Military Medicine for patents covering the use of BIO 300 as a medical radiation countermeasure.

The objective in the development of BIO 300 is to provide a treatment for members of the military, first responders and the civilian population who may be the targets of a radiological or nuclear event, according to Humanetics.

However, the Minneapolis-based company said it also will focus on applications in medical diagnostics—particularly in the area of CT scans, which have been linked recently to excessive levels of ionizing radiation.

BIO 300 has been developed by researchers at the Armed Forces Radiobiology Research Institute, a research institute within the Uniformed Services University of the Health Sciences and the National Institutes of Health.

The radiation countermeasure drug candidate is currently in Phase II clinical trials and patents have now been issued in the U.S., Europe and Australia, with others pending in Japan and Canada.